Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing

Set Alert for Manufacturing

Deficient DMFs Jeopardizing Timely Approvals of ANDAs

The pressure is on for API makers to submit higher quality Type II drug master files, or DMFs. FDA official says many US ANDA approvals are delayed by poor quality DMFs. A representative of the generic drug industry, however, contends that FDA is partially to blame for this problem by setting impractical expectations and an unrealistically high bar for DMFs.

Manufacturing Quality BioPharmaceutical
Advertisement

Latest From Manufacturing

White House Mulls Proposal To Pause FDA's Quality Metrics Initiative

Trump administration briefing materials show that the pharmaceutical industry's complaints about FDA's quality metrics initiative are getting high-level attention.

Quality Manufacturing

Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes

US FDA hands Pfizer its second complete response letter for its proposed biosimilar to Epogen/Procrit, citing manufacturing compliance concerns at a legacy Hospira manufacturing facility in Kansas that was the target of a February warning letter. Issue “is not directly related to EPO itself,” Pfizer’s Salomon Azoulay says.

Biosimilars Complete Response Letters

FDA, Justice Department Hit Sonar And Stratus With Drug GMP Consent Decree

Sonar Products and Stratus Pharmaceutical must operate under the terms of a Justice Department consent decree after failing to correct microbiological contamination and other drug GMP problems FDA identified, or obtain FDA approval for dermatological drug products they were marketing.

Manufacturing Quality

Regulators Accepting Predictive Stability Data In Lieu of Long-Term Studies

A growing number of pharmaceutical manufacturers are using predictive stability models to accelerate stability testing of their products for a wide range of applications. Regulators worldwide are also starting to accept predictive stability studies in lieu of full stability data in approving new drugs.

Manufacturing Quality

WHO Consults On Standardized Approach To Verifying Good Practices At Foreign Sites

The World Health Organization has prepared a draft list of documents and certificates that national regulatory authorities can rely on to verify compliance with the most relevant good practices in relation to medicinal products that underwent manufacturing and clinical trials at foreign sites. The proposed approach can reduce duplicate, and the frequency of, inspections.

Regulation Manufacturing

Genentech's Ocrevus Manufacturing Process Still A Work In Progress

Genentech overcame objections from US FDA quality reviewers to win approval of Ocrevus for multiple sclerosis by adding release and stability testing and committing to resolving process control issues, while suspending plans to accelerate post-approval manufacturing changes.

Quality Manufacturing
See All
UsernamePublicRestriction

Register